Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer

Abstract

CAP-CRT remains the superior regimen. SCALOP showed that patients with CA19.9 <46 IU ml^-1 after induction chemotherapy are more likely to benefit from CRT.